# Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

> **NCT00104923** · PHASE1 · COMPLETED · sponsor: **California Cancer Consortium** · enrollment: 29 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** fenretinide

## Key facts

- **NCT ID:** NCT00104923
- **Lead sponsor:** California Cancer Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104923, "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00104923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*